# First in Human Study of M4344 in Participants With Advanced Solid Tumors

> **NCT02278250** · PHASE1 · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 97 (actual)

## Conditions studied

- Solid Tumor
- Advanced Solid Tumor

## Interventions

- **DRUG:** M4344 10 mg BIW
- **DRUG:** M4344 20 mg BIW
- **DRUG:** M4344 40 mg BIW
- **DRUG:** M4344 80 mg BIW
- **DRUG:** M4344 160 mg BIW
- **DRUG:** M4344 300 mg BIW
- **DRUG:** M4344 450 mg BIW
- **DRUG:** M4344 700 mg BIW
- **DRUG:** M4344 1050 mg BIW
- **DRUG:** M4344 1200 mg BIW
- **DRUG:** M4344 100 mg BID
- **DRUG:** M4344 150 mg QD
- **DRUG:** M4344 250 mg QD
- **DRUG:** M4344 350 mg QD
- **DRUG:** M4344 400 mg
- **DRUG:** M4344 500 mg
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02278250
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-26
- **Primary completion:** 2021-06-16
- **Final completion:** 2021-09-24
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2023-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02278250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02278250, "First in Human Study of M4344 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02278250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*